<DOC>
	<DOC>NCT00849030</DOC>
	<brief_summary>The aim of this study is to test whether Arimidex alone or in combination with Tamoxifen is beneficial in the treatment of breast cancer.</brief_summary>
	<brief_title>ATAC - Arimidex, Tamoxifen Alone or in Combination</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Patients with histologically proven operable invasive breast cancer Patients who have completed all primary surgery and chemotherapy (if given), and are candidates to receive hormonal adjuvant therapy Women defined as postmenopausal Patients in whom there is any clinical evidence of metastatic disease Patients who, for whatever reason (e.g. confusion, infirmity, alcoholism), are unlikely to comply with trial requirements Patients whose chemotherapy was started more than 8 weeks (ie 56 days) after completion of primary surgery or whose chemotherapy was completed more than 8 weeks (ie 56 days) before starting randomised treatment</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>